Cargando…

The Possible Effect of the Long-Term Use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Hba1c and Lipid Profile in Type 2 Diabetes Mellitus: A Retrospective Study in KAUH, Jeddah, Saudi Arabia

(1) Background: Type 2 diabetes (T2DM) is a chronic metabolic disease with serious health complications. T2DM is associated with many chronic illnesses, including kidney failure, cardiovascular diseases (CVD), vision loss, and other related diseases. Obesity is one of the major factors associated wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ajabnoor, Ghada M. A., Hashim, Kamal Talat, Alzahrani, Mohammed Meshari, Alsuheili, Abdullah Zeid, Alharbi, Abdullah Fahad, Alhozali, Amani Matook, Enani, Sumia, Eldakhakhny, Basmah, Elsamanoudy, Ayman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046996/ https://www.ncbi.nlm.nih.gov/pubmed/36975599 http://dx.doi.org/10.3390/diseases11010050

Ejemplares similares

The Effect of Chronic Laxative Use on Lipid Profile and HbA1c: A Hospital-Based Retrospective Study
por: Ajabnoor, Ghada, et al.
Publicado: (2023)

The Association between Dyslipidemia, Dietary Habits and Other Lifestyle Indicators among Non-Diabetic Attendees of Primary Health Care Centers in Jeddah, Saudi Arabia
por: Enani, Sumia, et al.
Publicado: (2020)

ABCA1 C69T Gene Polymorphism Association with Dysglycemia in Saudi Prediabetic Adults
por: Ajabnoor, Ghada M. A., et al.
Publicado: (2022)

Association Between Anthropometric Indices and Nonanthropometric Components of Metabolic Syndrome in Saudi Adults
por: Al-Ahmadi, Jawaher, et al.
Publicado: (2022)

The Interplay of Vitamin D Deficiency and Cellular Senescence in The Pathogenesis of Obesity-Related Co-Morbidities
por: Bima, Abdulhadi, et al.
Publicado: (2021)

The Association Between Dietary Habits and Other Lifestyle Indicators and Dysglycemia in Saudi Adults Free of Previous Diagnosis of Diabetes
por: Jambi, Hanan, et al.
Publicado: (2020)

Gender Differences in The Factors associated with Hypertension in Non-Diabetic Saudi Adults—A Cross-Sectional Study
por: Al-Raddadi, Rajaa, et al.
Publicado: (2021)

Discrimination Power of Short Essay Questions Versus Multiple Choice Questions as an Assessment Tool in Clinical Biochemistry
por: Eldakhakhny, Basmah, et al.
Publicado: (2023)

Exploring the Validity of Available Markers and Indices in the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) in People with Type 2 Diabetes in Saudi Arabia
por: Ajabnoor, Ghada M. A., et al.
Publicado: (2023)

Association between laboratory markers and Covid-19 disease severity and outcome: a retrospective cohort study in Saudi Arabia
por: Alamoudi, Aliaa Amr, et al.
Publicado: (2023)

Assessment of Different Types of Strabismus Among Pediatric Patients in a Tertiary Hospital in Jeddah
por: Qanat, Ahmed S, et al.
Publicado: (2020)

Low-Carbohydrate High-Fat Diet: A SWOC Analysis
por: Nuwaylati, Dena, et al.
Publicado: (2022)

Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP‐1 RA use at screening
por: Rosenstock, Julio, et al.
Publicado: (2021)

Modulation of Dyslipidemia Markers Apo B/Apo A and Triglycerides/HDL-Cholesterol Ratios by Low-Carbohydrate High-Fat Diet in a Rat Model of Metabolic Syndrome
por: Alnami, Abrar, et al.
Publicado: (2022)

Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use
por: Kalra, Sanjay, et al.
Publicado: (2015)

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
por: Cheng, Dihe, et al.
Publicado: (2022)

Impact of the COVID-19 pandemic on imaging case volumes in King Abdullah University Hospitals (KAUH)
por: Gharaibeh, Maha, et al.
Publicado: (2023)

Glucagon, GLP-1 and Thermogenesis
por: González-García, Ismael, et al.
Publicado: (2019)

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
por: Lisco, Giuseppe, et al.
Publicado: (2022)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population
por: Nguyen, Hiep, et al.
Publicado: (2017)

GLP-1 RA Improves Diabetic Retinopathy by Protecting the Blood-Retinal Barrier through GLP-1R-ROCK-p-MLC Signaling Pathway
por: Wei, Liufeng, et al.
Publicado: (2022)

Hijama (wet cupping therapy) enhances oral and dental health by improving salivary secretion volume and pH in adult patients at King Abdul Aziz University Hospital (KAUH), Jeddah, KSA: A controlled trial study
por: Bukhary, Fouzia A., et al.
Publicado: (2022)

Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9–36 Amide at the GLP-1 Receptor
por: Li, Naichang, et al.
Publicado: (2012)

THU275 Tacrolimus Levels And Kidney Function In Kidney Transplanted (KT) Patients With Diabetes On Glucagon Like-1 Receptor Agonists (GLP1-RA)
por: Campana, Mario S, et al.
Publicado: (2023)

GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
por: Xiang, Jie, et al.
Publicado: (2023)

SARS-CoV-2 Omicron symptoms and adverse effects of GLP-1 RA therapy
por: Jensterle, Mojca, et al.
Publicado: (2022)

The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial
por: Mitchell, James L, et al.
Publicado: (2023)

Clinico-Pathological Outcomes of Patients With Crescentic Glomerulonephritis: A Single-Center Study
por: Alsuheili, Abdullah Z, et al.
Publicado: (2023)

Relationship between admission criteria and academic performance in basic science courses in health science colleges in KAU
por: Alamoudi, Aliaa Amr, et al.
Publicado: (2021)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Evaluation of early biomarkers of renal dysfunction in diabetic patients
por: Al-Hazmi, Shrouq F., et al.
Publicado: (2020)

GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
por: Divino, Victoria, et al.
Publicado: (2017)

Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review
por: Jensterle, Mojca, et al.
Publicado: (2022)

Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature
por: Posso-Osorio, Iván, et al.
Publicado: (2023)

Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
por: Caparrotta, Thomas M., et al.
Publicado: (2021)

Depression Among Patients With Type 2 Diabetes Mellitus at King Abdulaziz University Hospital (KAUH): A Cross-Sectional Study
por: Al Qusaibi, Bader, et al.
Publicado: (2022)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Optimal Glycemic Control in a Patient With HNF1A MODY With GLP-1 RA Monotherapy: Implications for Future Therapy
por: Fantasia, Kathryn L, et al.
Publicado: (2019)

ODP171 Choosing GLP-1RA Over Insulin for Patients with Type 2 Diabetes and Severe Hyperglycemia
por: Mamtani, Raashi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5of5vj59thvpl3gs9d6q816c1q